OPKO Health, Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
OPKO Health, Inc. (OPK) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of -$943.00 thousand for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2013-08-09
- OPKO Health, Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2013-06-30 was -$943.00K.
- OPKO Health, Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2013-03-31 was -$597.00K.
- OPKO Health, Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2012-06-30 was $0.00.
- OPKO Health, Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2012 was -$585.00K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|
| 2013-06-30 | -$943.00K 10-Q · filed 2013-08-09 | -$1.54M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | -$597.00K 10-Q · filed 2013-05-10 | ||
| 2012-12-31 | -$585.00K 10-K · filed 2013-03-18 | ||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |